Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Antimicrobial Agents and Chemotherapy
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions

caspofungin

  • Efg1 and Cas5 Orchestrate Cell Wall Damage Response to Caspofungin in <span class="named-content genus-species" id="named-content-1">Candida albicans</span>
    Mechanisms of Action: Physiological Effects
    Efg1 and Cas5 Orchestrate Cell Wall Damage Response to Caspofungin in Candida albicans

    Echinocandins are recommended as the first-line drugs for the treatment of systemic candidiasis. Cas5 is a key transcription factor involved in the response to cell wall damage induced by echinocandins.

    Kang Xiong, Chang Su, Qiangqiang Sun, Yang Lu
  • Impact of Loading Dose of Caspofungin in Pharmacokinetic-Pharmacodynamic Target Attainment for Severe Candidiasis Infections in Patients in Intensive Care Units: the CASPOLOAD Study
    Pharmacology
    Impact of Loading Dose of Caspofungin in Pharmacokinetic-Pharmacodynamic Target Attainment for Severe Candidiasis Infections in Patients in Intensive Care Units: the CASPOLOAD Study

    This study evaluated the impact of a high loading dose of caspofungin (CAS) on the pharmacokinetics of CAS and the pharmacokinetic-pharmacodynamic (PK-PD) target attainment in patients in intensive care units (ICU). ICU patients requiring CAS treatment were prospectively included to receive a 140-mg loading dose of CAS. Plasma CAS concentrations (0, 2, 3, 5, 7, and 24 h postinfusion) were determined to develop a two-compartmental...

    Sébastien Bailly, Elodie Gautier-Veyret, Minh P. Lê, Lila Bouadma, Olivier Andremont, Mathilde Neuville, Bruno Mourvillier, Romain Sonneville, Eric Magalhaes, Jordane Lebut, Aguila Radjou, Roland Smonig, Michel Wolff, Laurent Massias, Claire Dupuis, Jean-François Timsit
  • Open Access
    Population Pharmacokinetics of Caspofungin among Extracorporeal Membrane Oxygenation Patients during the Postoperative Period of Lung Transplantation
    Pharmacology
    Population Pharmacokinetics of Caspofungin among Extracorporeal Membrane Oxygenation Patients during the Postoperative Period of Lung Transplantation

    Little is known about the influence of extracorporeal membrane oxygenation (ECMO) on the pharmacokinetics (PK) of caspofungin. The aim of this study was to describe population PK of caspofungin in patients with and without ECMO during the postoperative period of lung transplantation (LTx) and to investigate covariates influencing caspofungin PK. We compared ECMO patients with non-ECMO patients, and patients before and after ECMO weaning...

    Qianlin Wang, Zhu Zhang, Donglin Liu, Wenqian Chen, Gang Cui, Pengmei Li, Xianglin Zhang, Min Li, Qingyuan Zhan, Chen Wang
  • Unexpected Cell Wall Alteration-Mediated Bactericidal Activity of the Antifungal Caspofungin against Vancomycin-Resistant <span class="named-content genus-species" id="named-content-1">Enterococcus faecium</span>
    Editor's Pick Mechanisms of Action: Physiological Effects
    Unexpected Cell Wall Alteration-Mediated Bactericidal Activity of the Antifungal Caspofungin against Vancomycin-Resistant Enterococcus faecium

    Enterococcus faecium has become a major opportunistic pathogen with the emergence of vancomycin-resistant enterococci (VRE). As part of the gut microbiota, they have to cope with numerous stresses, including effects of antibiotics and other xenobiotics, especially in patients hospitalized in intensive care units (ICUs) who receive many medications. The aim of this...

    Christophe Isnard, Sara B. Hernandez, François Guérin, Fanny Joalland, Didier Goux, François Gravey, Michel Auzou, David Enot, Pierrick Meignen, Jean-Christophe Giard, Felipe Cava, Vincent Cattoir
  • Open Access
    Caspofungin Weight-Based Dosing Supported by a Population Pharmacokinetic Model in Critically Ill Patients
    Pharmacology
    Caspofungin Weight-Based Dosing Supported by a Population Pharmacokinetic Model in Critically Ill Patients

    The objective of this study was to develop a population pharmacokinetic model and to determine a dosing regimen for caspofungin in critically ill patients. Nine blood samples were drawn per dosing occasion. Fifteen patients with (suspected) invasive candidiasis had one dosing occasion and five had two dosing occasions, measured on day 3 (±1) of treatment. Pmetrics was used for population pharmacokinetic modeling and probability of...

    Anne-Grete Märtson, Kim C. M. van der Elst, Anette Veringa, Jan G. Zijlstra, Albertus Beishuizen, Tjip S. van der Werf, Jos G. W. Kosterink, Michael Neely, Jan-Willem Alffenaar
  • Open Access
    Nonstationary Pharmacokinetics of Caspofungin in ICU Patients
    Pharmacology
    Nonstationary Pharmacokinetics of Caspofungin in ICU Patients

    Standard dosing of caspofungin in critically ill patients has been reported to result in lower drug exposure, which can lead to subtherapeutic 24-h area under the curve to MIC (AUC0–24/MIC) ratios. The aim of the study was to investigate the population pharmacokinetics of caspofungin in a cohort of 30 intensive care unit patients with a suspected invasive fungal infection, with a large proportion of patients requiring...

    Agnieszka Borsuk-De Moor, Justyna Sysiak-Sławecka, Elżbieta Rypulak, Michał Borys, Paweł Piwowarczyk, Grzegorz Raszewski, Dariusz Onichimowski, Mirosław Czuczwar, Paweł Wiczling
  • The Novel Arylamidine T-2307 Demonstrates <em>In Vitro</em> and <em>In Vivo</em> Activity against <span class="named-content genus-species" id="named-content-1">Candida auris</span>
    Experimental Therapeutics
    The Novel Arylamidine T-2307 Demonstrates In Vitro and In Vivo Activity against Candida auris

    The in vitro and in vivo activity of the arylamidine T-2307 against Candida auris was evaluated. T-2307 demonstrated in vitro activity (MIC ranges ≤ 0.008 to 0.015 μg/ml at 50% inhibition; 0.125 to >4 μg/ml at 100% inhibition).

    Nathan P. Wiederhold, Laura K. Najvar, Rosie Jaramillo, Marcos Olivo, Hoja Patterson, April Connell, Yoshiko Fukuda, Junichi Mitsuyama, Gabriel Catano, Thomas F. Patterson
  • Caspofungin and <em>Pneumocystis</em> Pneumonia: It Is Time To Go Ahead
    Letter to the Editor
    Caspofungin and Pneumocystis Pneumonia: It Is Time To Go Ahead
    Gilles Nevez, Solène Le Gal
  • Genomewide Elucidation of Drug Resistance Mechanisms for Systemically Used Antifungal Drugs Amphotericin B, Caspofungin, and Voriconazole in the Budding Yeast
    Mechanisms of Resistance
    Genomewide Elucidation of Drug Resistance Mechanisms for Systemically Used Antifungal Drugs Amphotericin B, Caspofungin, and Voriconazole in the Budding Yeast

    There are only a few antifungal drugs used systemically in treatment, and invasive fungal infections that are resistant to these drugs are an emerging problem in health care. In this study, we performed a high-copy-number genomic DNA (gDNA) library screening to find and characterize genes that reduce susceptibility to amphotericin B, caspofungin, and voriconazole in ...

    Cigdem Balkan, Ilkcan Ercan, Esin Isik, Esra Sahin Akdeniz, Orhan Balcioglu, Marie Kodedová, Olga Zimmermannová, Muhammed Dundar, Hana Sychrová, Ahmet Koc
  • Echinocandins for the Treatment of Invasive Aspergillosis: from Laboratory to Bedside
    Minireview
    Echinocandins for the Treatment of Invasive Aspergillosis: from Laboratory to Bedside

    Echinocandins (caspofungin, micafungin, anidulafungin), targeting β-1,3-glucan synthesis of the cell wall, represent one of the three currently available antifungal drug classes for the treatment of invasive fungal infections. Despite their limited antifungal activity against Aspergillus spp., echinocandins are considered an alternative option for the treatment of invasive aspergillosis (IA).

    Marion Aruanno, Emmanouil Glampedakis, Frédéric Lamoth

Pages

  • Next
  • 1
  • 2
Back to top

About

  • About AAC
  • Editor in Chief
  • Editorial Board
  • Policies
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • AAC Podcast
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Ethics
  • Contact Us

Follow #AACJournal

@ASMicrobiology

       

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0066-4804; Online ISSN: 1098-6596